Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S912000
Reexamination Certificate
active
06906077
ABSTRACT:
Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the treatment of glaucomatous neuropathy.
REFERENCES:
patent: 4550022 (1985-10-01), Garabedian et al.
patent: 5641749 (1997-06-01), Yan et al.
patent: 5641750 (1997-06-01), Louis
patent: 98/10758 (1998-10-01), None
Van Buskirk, et al., “Predicted outcome from hypotensive therapy for glaucomatous optic neuropathy,”Am. J. Ophthalmol., vol. 116(5):636-640, (1993).
Schumer, et al., “The nerve of glaucoma!,”Arch. Ophthalmol., vol. 112:37-44, (1994).
Raff, et al., “Programmed cell death and the control of cell survival: lessons from the nervous systems,”Science, vol. 262:695-700, (1993).
Anderson, et al., “Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve,”Invest. Ophthalmol., vol. 13(10):771-783, (1974).
Quigley, et al., “The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve,”Invest. Ophthalmol., vol. 15(8):606-616, (1976).
Mansour-Robaey, et al., “Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion . . . ,”Proc. Natl. Acad. Sci. USA, vol. 91:1632-1636, (1994).
Meyer-Franke, et al., “Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture,”Neuron, vol. 15:805-819, (1995).
Cui, et al., “NT-4/5 reduces naturally occurring retinal ganglion cell death in neonatal rats,”Neuroreport, vol. 5(15):1882-1884, (1994).
Lewin, et al., “Physiology of the neurotrophins,”Ann. Rev. Neurosci., vol. 19:289-317, (1996).
Segal, et al., “Intracellular signaling pathways activated by neurotrophic factors,”Ann. Rev. Neurosci., vol. 19:463-489, (1996).
Ebadi, et al., “Neurotrophins and their receptors in nerve injury and repair,”Neurochem Int., vol. 30(4/5):347-374, (1997).
Kaplan, et al., “Signal transduction by the neurotrophin receptors,”Curr. Opin. Cell Biol., vol. 9:213-221, (1997).
Jelsma, et al., “Different forms of the neurotrophin receptor trkB mRNA predominate in rat retina and optic nerve,”J. Neurobiol., vol. 24(9):1207-1214, (1993).
Rickman, et al., “Expression of the protooncogene,trk, receptors in the developing rat retina,”Vis. Neurosci., vol. 12:215-222, (1995).
Ugolini, et al., “TrkA, TrkB and p75 mRNA expression is developmentally regulated in the rat retina,”Brain Res, vol. 704:121-124, (1995).
Cellerino, et al., “Brain-derived neurotrophic factor
eurotrophin-4 receptor TrkB is localized on ganglion cells and Dopaminergics amacrine cells in the vertebrate retina,”J. Comp. Neurol., vol. 386:149-160, (1997).
Gao, et al., “Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after Optic nerve injury,”Invest. Ophthalmol. Vis. Sci., vol. 38(9):1840-1847, (1997).
Lindholm, et al., “Brain-derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity,”Eur. J. Neurosci., vol. 5:1455-1464, (1993).
Unoki, et al., “Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary Neurotrophic factor, and basic fibroblast growth factor,”Invest. Ophthalmol. Vis. Sci., vol. 35(3):907-915, (1994).
Beck, et al., “Brain-derived neurotrophic factor protects against ischemic cell damage in the rat hippocampus,”J. Cereb. Blood. Flow Metab., vol. 14:689-692, (1994).
Kirsch, et al., “Evidence for multiple, local functions of ciliary neurotrophic factor (CNTF) in retinal development: expression of CNTF and its receptors and in vitro . . . ,”J. Neurochem., vol. 68(3):979-990, (1997).
Mey, et al., “Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo,”Brain Res., vol. 602:304-317, (1993).
Weibel, et al., “Brain-derived neurotrophic factor (BDNF) prevents lession-induced axonal die-back in young rat optic nerve,”Brain Res., vol. 679:249-254, (1995).
Graul & Castaner, “AIT-082,”Drugs of the Future, vol. 22(9):945-947, (1997).
Nabeshima, et al., “Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats,”Gerontology, vol. 40(2):46-56, (1994).
Matsui, et al., “Protective effects of ONO-2506 on neurological deficits and brain infarct volume following 1 week of permanent occlusion of middle cerebral . . . ,”Society for Neurosci. Abstracts, vol. 24:254, (1998).
Gronborg, et al., “Neuroprotection by a novel compound, NS521,”Society for Neurosci. Abstracts, vol. 24:1551, (1998).
Aimone, et al., “The 1α,25(OH)2D3analog CB-1093 induces nerve growth factor in non-human primate brain,”Society for Neurosci. Abstracts, vol. 24:292, (1998).
Culmsee, et al., “NGF antisense oligonucleotide blocks protective effects of clenbuterol against glutamate-Induced excitotoxicity in vitro and focal cerebral . . . , ”Society for Neurosci. Abstracts, vol. 24:295, (1998).
Takahashi, N. et al., “Rat retinal ganglion cells in culture,”Exp. Eye Res., vol. 53:565-572, (1991).
Shinoda, et al., “Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells,”Biochem. Pharmacol., vol. 39(11):1813-1816, (1990).
Nabeshima, et al., “Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model: oral administration of propentofylline..,”Jpn. J. Psychol. Pharmacol., vol. 13:89-95, (1993).
Ophthalmic Surgery: Principles of Practice, Ed., G.L. Spaeth, W.B. Sanders Co., Philadelphia, PA, U.S.A., p. 85-87, (1990).
Hammes, et al., “Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology In experimental diabetics,”Molecular Medicine, vol. 1(5):527-534, Jul. 1995.
Rathbone, et al., “Physiology and pharmacology of natural and synthetic nonadenine-based purines in the nervous system,”Drug Development Research, vol. 45:356-372, (1998).
Takeda Chem Ind, Ltd., “New drug prevent treat diabetes complicated comprise benzoquinone hydroquinone form treat . . . ,” Derwent Publications, Ltd., London XP-002136481 & JP 05 009114A, Jan. 19, 1993 abstract.
Yamamoto, et al., “Neuroprotective effect of 41-(4-methylphenyl)-2,21=:61,2-terpyridine trihydrochloride, a novel inducer of nerve growth factor,”Life Sciences, vol. 59(25/26):2139-2146, (1996).
Nitta, et al., “Oral administration of idebenone induces nerve growth factor in the brain and improves learning..,”Archives of Pharmacology, vol. 349:401-407, (1994).
Culmsee, et al., “Neuroprotection by drug-induced growth factors,”Pharmacology of Cerebral Ischemia, 7th, pp. 333-348, (1999).
Semkova, et al., “Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischemic damage and attenuates glutamate neurotoxicity in clutured hippocampal . . . ,”Brain Research, vol. 717:44-54, (1996).
Riaz, et al., “A vitamin D3derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats,” Diabetologia, vol. 42:1308-1313, (1999).
Gronborg, et al., “Neuroprotection by a novel compound, NS5211,”The Journal of Pharmacology and Experimental Therapeutics, vol. 290(1):348-353, (1999).
Middlemiss, P.J., et al., (Geerts, Hugo), “AIT—082, a unique purine derivative, enhanc
Alcon Manufacturing Ltd.
Fay Zohreh
Schultz Teresa J.
LandOfFree
Use of neurotrophic factor stimulators for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of neurotrophic factor stimulators for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of neurotrophic factor stimulators for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3495933